Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives $42.60 Consensus Target Price from Brokerages

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) have earned a consensus recommendation of “Moderate Buy” from the five brokerages that are covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $42.60.

COLL has been the subject of several recent analyst reports. HC Wainwright boosted their target price on Collegium Pharmaceutical from $47.00 to $50.00 and gave the stock a “buy” rating in a research note on Thursday, September 5th. Piper Sandler restated a “neutral” rating and set a $37.00 price objective on shares of Collegium Pharmaceutical in a research report on Friday, October 11th. Needham & Company LLC reaffirmed a “hold” rating on shares of Collegium Pharmaceutical in a research report on Friday, August 9th. Truist Financial boosted their price target on shares of Collegium Pharmaceutical from $40.00 to $42.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Finally, StockNews.com lowered Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 23rd.

Insiders Place Their Bets

In other news, EVP Thomas B. Smith sold 9,593 shares of the company’s stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $36.62, for a total transaction of $351,295.66. Following the completion of the sale, the executive vice president now owns 53,816 shares in the company, valued at $1,970,741.92. This represents a 15.13 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Shirley R. Kuhlmann sold 19,248 shares of Collegium Pharmaceutical stock in a transaction on Thursday, September 5th. The shares were sold at an average price of $38.30, for a total transaction of $737,198.40. Following the completion of the transaction, the executive vice president now owns 120,161 shares in the company, valued at approximately $4,602,166.30. This trade represents a 13.81 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 3.98% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Pacer Advisors Inc. grew its holdings in Collegium Pharmaceutical by 31.8% during the second quarter. Pacer Advisors Inc. now owns 3,408,369 shares of the specialty pharmaceutical company’s stock worth $109,749,000 after acquiring an additional 821,541 shares during the period. Rubric Capital Management LP grew its stake in shares of Collegium Pharmaceutical by 27.2% during the 2nd quarter. Rubric Capital Management LP now owns 2,333,500 shares of the specialty pharmaceutical company’s stock worth $75,139,000 after purchasing an additional 499,473 shares during the period. Vanguard Group Inc. increased its holdings in shares of Collegium Pharmaceutical by 0.8% in the 1st quarter. Vanguard Group Inc. now owns 2,330,728 shares of the specialty pharmaceutical company’s stock valued at $90,479,000 after purchasing an additional 17,942 shares in the last quarter. Principal Financial Group Inc. lifted its stake in shares of Collegium Pharmaceutical by 3.9% in the third quarter. Principal Financial Group Inc. now owns 1,745,818 shares of the specialty pharmaceutical company’s stock valued at $67,459,000 after purchasing an additional 64,958 shares during the period. Finally, Renaissance Technologies LLC boosted its holdings in Collegium Pharmaceutical by 8.0% during the second quarter. Renaissance Technologies LLC now owns 1,531,498 shares of the specialty pharmaceutical company’s stock worth $49,314,000 after buying an additional 113,300 shares in the last quarter.

Collegium Pharmaceutical Stock Up 1.3 %

Shares of NASDAQ COLL opened at $31.19 on Friday. The business has a 50-day moving average of $35.56 and a two-hundred day moving average of $34.68. The company has a market capitalization of $1.01 billion, a price-to-earnings ratio of 13.27 and a beta of 0.95. Collegium Pharmaceutical has a 1 year low of $25.16 and a 1 year high of $42.29. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.